Get the Stockscreener App
0.00
100.00%
-9.71
Fibrogen Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.
See More
Previous Close:
$9.71
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$39.28M
Revenue:
$147.75M
Net Income/Loss:
$-284.23M
P/E Ratio:
0.00
EPS:
-2.93
Net Cash Flow:
$-317.54M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$12.60
Fibrogen Inc Stock (FGEN) Company Profile
Name
Fibrogen Inc
Sector
Industry
Phone
415-978-1200
Address
350 BAY STREET, SAN FRANCISCO, CA
Compare FGEN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
0.00 | 39.28M | 147.75M | -284.23M | -317.54M | -2.93 |
VRTX
Vertex Pharmaceuticals Inc
|
428.17 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
744.48 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
786.13 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.77 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.99 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-26-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-26-23 | Downgrade | Stifel | Buy → Hold |
| Jun-26-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-02-23 | Upgrade | Stifel | Hold → Buy |
| Jan-31-23 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-05-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-22-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-20-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-16-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-16-21 | Downgrade | Stifel | Buy → Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-07-21 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-21 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-02-21 | Downgrade | Jefferies | Buy → Hold |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
| Oct-26-20 | Initiated | Raymond James | Underperform |
| Jul-10-20 | Resumed | Stifel | Buy |
| May-01-20 | Initiated | Cowen | Market Perform |
| Apr-27-20 | Initiated | BofA/Merrill | Neutral |
| May-29-19 | Resumed | Goldman | Neutral |
| May-10-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-19 | Initiated | Piper Jaffray | Neutral |
| Feb-11-19 | Resumed | Stifel | Buy |
| Dec-19-18 | Upgrade | Citigroup | Neutral → Buy |
| Aug-08-17 | Reiterated | Leerink Partners | Outperform |
| Aug-08-17 | Reiterated | Stifel | Buy |
| Jul-21-17 | Downgrade | Goldman | Buy → Neutral |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Feb-11-16 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
| Dec-04-15 | Initiated | Citigroup | Buy |
| Sep-23-15 | Initiated | Lake Street | Hold |
| Jul-29-15 | Initiated | Citigroup | Buy |
| Jul-20-15 | Upgrade | Goldman | Neutral → Buy |
| Dec-09-14 | Initiated | Stifel | Buy |
View All
Fibrogen Inc Stock (FGEN) Latest News
FibroGen Shareholder Alert - TMX Newsfile
FibroGen Inc stock (US3156631046): Is its hypoxia-inducible factor focus still the real test for bio - AD HOC NEWS
Kyntra Bio, Inc. Files 8-K Current Report with SEC – Company Information, Address, and NASDAQ Listing Details - Minichart
Nasdaq warns Kyntra Bio (NASDAQ: FGEN) over Global Select listing test - Stock Titan
Nasdaq Moves: Can FibroGen Inc sustain its profitability2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Retail Trends: What is the target price for FibroGen Inc stock2026 Summary & Verified Short-Term Plans - baoquankhu1.vn
Sentiment Review: Will FibroGen Inc benefit from government policy2026 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
FibroGen Inc stock: What investors need to know now - AD HOC NEWS
Kyntra Bio CEO to webcast April 13 presentation at Needham event - Stock Titan
Aug Sentiment: Is FibroGen Inc stock a value trap2026 Momentum Check & Reliable Momentum Entry Alerts - baoquankhu1.vn
FibroGen Inc Stock: Biotech Innovator Focused on Hypoxia Pathways and Oncology for Long-Term Investo - AD HOC NEWS
FGEN SEC FilingsFibrogen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Setups: What is the long term forecast for FibroGen Inc stock2026 Risk Factors & Daily Volume Surge Signals - baoquankhu1.vn
Kyntra Bio (MEX:KYNB) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
Aug Macro: Can FibroGen Inc sustain its profitability2026 Intraday Action & Trade Opportunity Analysis Reports - baoquankhu1.vn
Rate Cut: What is the long term forecast for FibroGen Inc stock2026 PostEarnings & Weekly Breakout Watchlists - baoquankhu1.vn
FibroGen Inc stock leads biotech gains on China asset sale and FDA update amid Q4 earnings scrutiny - AD HOC NEWS
FibroGen Inc stock faces renewed scrutiny amid expanding interstitial lung disease pipeline competit - AD HOC NEWS
If You Invested $1,000 in Fibrogen Inc (FGEN) - Stock Titan
Akebia Therapeutics, Inc. v. FibroGen, Inc. - Law.com
FibroGen Inc stock faces scrutiny ahead of delayed Q4 earnings release amid pipeline pressures - AD HOC NEWS
Revenue of Fibrogen from 2020 to 2024 - Statista
Breakout Watch: Is FibroGen Inc stock a value trapPortfolio Update Report & Smart Investment Allocation Insights - baoquankhu1.vn
KYNB: Cash runway extended to 2028 as FG-3246 and roxadustat advance in key late-stage trials - TradingView
Kyntra Bio (KYNB) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript - The Globe and Mail
Kyntra Bio: Q4 Earnings Snapshot - marketscreener.com
Kyntra Bio (NASDAQ: KYNB) pivots to oncology and advances FG-3246, roxadustat - Stock Titan
Kyntra Bio (Nasdaq: KYNB) unveils 2025 results, FG-3246 and roxadustat plans - Stock Titan
New prostate cancer drug trial advances as Kyntra Bio cuts 2025 loss - Stock Titan
FibroGen Q4 2025 earnings preview - MSN
FibroGen (KYNB) Set to Announce Q4 Earnings with Significant Dec - gurufocus.com
Bull Run: What is the long term forecast for FibroGen Inc stock2026 Intraday Action & Fast Moving Stock Trade Plans - baoquankhu1.vn
Kyntra Bio (KYNB) CEO reports 277-share tax withholding event - Stock Titan
Tax withholding slightly trims Kyntra Bio (KYNB) CFO share holdings - Stock Titan
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results - Yahoo Finance
Gains Report: Is FibroGen Inc stock a value trap2025 Market WrapUp & Long Hold Capital Preservation Plans - baoquankhu1.vn
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca - MSN
Quarterly Earnings: What is the target price for FibroGen Inc stockJobs Report & Safe Capital Investment Plans - baoquankhu1.vn
FGEN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Breakouts: Can FibroGen Inc be the next market leaderJuly 2025 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
What's Going On With Kyntra Bio Stock Tuesday? - Bitget
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 - marketscreener.com
Earnings Risk: Is FibroGen Inc stock a value trapWeekly Stock Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
FibroGen (FGEN) Delisted: What’s Really Left for Shareholders? - AD HOC NEWS
Analyst Upgrade: Why is FibroGen Inc stock going up2025 Performance Recap & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Kyntra Bio to Participate in Upcoming Investor Conferences - The Manila Times
Sentiment Recap: Is FibroGen Inc stock heavily shorted2025 Historical Comparison & Weekly Watchlist of Top Performers - baoquankhu1.vn
Support Test: Will FibroGen Inc. benefit from rising consumer demandPortfolio Gains Summary & High Accuracy Buy Signal Tips - mfd.ru
Can FibroGen Inc. sustain its profitabilityEarnings Trend Report & Reliable Price Breakout Alerts - mfd.ru
Aug Volume: Will Global Indemnity Group LLC Preferred Security benefit from geopolitical trendsVolume Spike & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Fibrogen Inc Stock (FGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrogen Inc Stock (FGEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Nov 13 '25 |
Buy |
9.18 |
1,000 |
9,180 |
22,239 |
| Schoeneck James A | Director |
Jun 30 '25 |
Buy |
5.07 |
23,567 |
119,485 |
39,666 |
1.73%
2.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):